Antimicrobial Activity of Fosfomycin-Tobramycin Combination against Pseudomonas aeruginosa Isolates Assessed by Time-Kill Assays and Mutant Prevention Concentrations
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The antibacterial activity of fosfomycin-tobramycin combination was studied by time-kill assay in eight Pseudomonas aeruginosa clinical isolates belonging to the fosfomycin wild-type population (MIC = 64 μg/ml) but with different tobramycin susceptibilities (MIC range, 1 to 64 μg/ml). The mutant prevention concentration (MPC) and mutant selection window (MSW) were determined in five of these strains (tobramycin MIC range, 1 to 64 μg/ml) in aerobic and anaerobic conditions simulating environments that are present in biofilm-mediated infections. Fosfomycin-tobramycin was synergistic and bactericidal for the isolates with mutations in the mexZ repressor gene, with a tobramycin MIC of 4 μg/ml. This effect was not observed in strains displaying tobramycin MICs of 1 to 2 μg/ml due to the strong bactericidal effect of tobramycin alone. Fosfomycin presented higher MPC values (range, 2,048 to >2,048 μg/ml) in aerobic and anaerobic conditions than did tobramycin (range, 16 to 256 μg/ml). Interestingly, the association rendered narrow or even null MSWs in the two conditions. However, for isolates with high-level tobramycin resistance that harbored aminoglycoside nucleotidyltransferases, time-kill assays showed no synergy, with wide MSWs in the two environments. glpT gene mutations responsible for fosfomycin resistance in P. aeruginosa were determined in fosfomycin-susceptible wild-type strains and mutant derivatives recovered from MPC studies. All mutant derivatives had changes in the GlpT amino acid sequence, which resulted in a truncated permease responsible for fosfomycin resistance. These results suggest that fosfomycin-tobramycin can be an alternative for infections due to P. aeruginosa since it has demonstrated synergistic and bactericidal activity in susceptible isolates and those with low-level tobramycin resistance. It also prevents the emergence of resistant mutants in either aerobic or anaerobic environments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Differential acquisition of resistance mutations in P. aeruginosa planktonic and biofilm growth have been documented in some cases, such as aminoglycoside (tobramycin) resistance development seemingly linked to LPS biosynthesis genes (orfKHLN) and electron transport chain components (cyoAB) [96,97].”
From Mechanisms of antibiotic resistance in Pseudomonas aeruginosa biofilms (2023) · cites this paper as [97]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients
Smith, E. E., Buckley, D. G., Wu, Z., Saenphimmachak, C., Hoffman, L. R., D’Argenio, D. A., Miller, S. I., Ramsey, B. W., Speert, D. P., Moskowitz, S. M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602138103 · Cited by 1,319
Pseudomonas aeruginosa : new insights into pathogenesis and host defenses
Gellatly, S. L., & Hancock, R. E. W. (2013) · Pathogens and Disease · doi:10.1111/2049-632x.12033 · Cited by 1,295
Research works printed but not linked: 30
- Morita Y, Tomida J, Kawamura Y. 2014. Responses of Pseudomonas aeruginosa to antimicrobials. Front Microbiol 4:422. · DOI · Paper page
- 10.1128/AAC.04238-14 · DOI
- 10.1590/0037-8682-0012-2013 · doi:10.1590/0037-8682-0012-2013
- 10.1128/AAC.02779-13 · doi:10.1128/aac.02779-13
- 10.1111/2049-632X.12015 · DOI
- 10.1164/rccm.201105-0924OC · DOI
- 10.1128/JB.00748-09 · DOI
- 10.1093/jmicro/dfh102 · doi:10.1093/jmicro/dfh102
- 10.1128/AAC.05958-11 · doi:10.1128/aac.05958-11
- 10.1128/JCM.00753-11 · DOI · Paper page
- Gobernado M. 2003. Fosfomicina. Rev Esp Quimioter 16:15–40.
- Alvarez F, Olaechea P, Grau S, Marín M, Domínguez A, Martínez-Lanao J, Soy D, Alos M, Victoria M, Sádaba B, Mediavilla A, Fatela D. Recomendaciones para la monitorización de antibióticos en pacientes críticos ingresados en UCI. Farm Hosp 32:113–123.
- Clinical and Laboratory Standards Institute. 1999. Methods for determining bactericidal activity of antimicrobial agents. Approved Standard M26-A. Clinical and Laboratory Standards Institute, Wayne, PA.
- 10.1371/journal.pone.0069763 · doi:10.1371/journal.pone.0069763
- 10.1093/jac/dkg269 · DOI · Paper page
- Maciá MD, Borrell N, Pérez JL, Oliver A. 2004. Detection and susceptibility testing of hypermutable Pseudomonas aeruginosa strains with the Etest and disk diffusion. Antimicrob Agents Chemother 48:7 2665–2672. · DOI
- 10.1128/AAC.00148-07 · DOI · Paper page
- 10.1128/AAC.47.6.1887-1894.2003 · DOI · Paper page
- 10.1128/AAC.43.11.2624 · DOI · Paper page
- 10.1016/j.eimc.2010.05.001 · DOI
- 10.1126/science.1087619 · DOI · Paper page
- 10.1038/35023079 · DOI · Paper page
- 10.1016/j.tim.2008.12.003 · DOI · Paper page
- 10.1172/JCI0213870 · DOI · Paper page
- 10.1128/AAC.00750-13 · DOI
- 10.1093/jac/dkp224 · doi:10.1093/jac/dkp224
- 10.1016/j.cbi.2004.05.005 · DOI
- 10.1128/AAC.01252-13 · DOI · Paper page
- 10.1128/AAC.00415-10 · DOI
- 10.1111/j.1749-6632.1974.tb43277.x · DOI · Paper page
Cited by
Mechanisms of antibiotic resistance in Pseudomonas aeruginosa biofilms
Fernández-Billón, M., Llambías-Cabot, A. E., Jordana-Lluch, E., Oliver, A., & Macià, M. D. (2023) · Biofilm · doi:10.1016/j.bioflm.2023.100129 · Cited by 170
Soares, A., Alexandre, K., & Etienne, M. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.02057 · Cited by 113
Metadata
- Authors
- Díez-Aguilar, M., Morosini, M. I., Tedim, A. P., Rodríguez, I., Aktaş, Z., & Cantón, R.
- Affiliations
- Servicio de Microbiología, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain
- Department of Clinical Microbiology, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2015-10
- Volume
- 59
- Issue
- 10
- Pages
- 6039-6045
- ISSN
- 0066-4804
- 1098-6596
- Cited by
- 37
- References
- 2
- Language
- en
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.